- Home
- BZFDW vs ORMP Comparison
BZFDW vs ORMP Comparison
Compare BZFDW & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BZFDW | ORMP |
|---|---|---|
| Founded | N/A | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 197.6M |
| IPO Year | 2020 | 2010 |
Fundamental Metrics
Financial Performance| Metric | BZFDW | ORMP |
|---|---|---|
| Price | $0.01 | $4.76 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 75.7K | ★ 160.5K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | ★ 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | N/A | ★ 2.76 |
| Revenue | ★ $185,266,000.00 | $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.74 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $0.00 | $2.09 |
| 52 Week High | $0.07 | $5.47 |
Technical Indicators
Market Signals| Indicator | BZFDW | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 32.79 | 51.06 |
| Support Level | $0.00 | $3.91 |
| Resistance Level | $0.03 | $5.01 |
| Average True Range (ATR) | 0.00 | 0.15 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 46.00 | 43.62 |
Price Performance
Historical ComparisonAbout BZFDW BuzzFeed Inc. Warrant
BuzzFeed Inc is a digital media company across pop culture, entertainment, shopping, food, and news, its brands drive conversation and inspire what audiences watch, read, and buy now and into the future. Its iconic, globally-loved brands include BuzzFeed, HuffPost, and Tasty. The company generates revenue from advertising, content, commerce, and other sources.
About ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.